Seres Therapeutics Inc (NASDAQ:MCRB) – Research analysts at Oppenheimer issued their FY2022 EPS estimates for shares of Seres Therapeutics in a research note issued to investors on Thursday. Oppenheimer analyst M. Breidenbach anticipates that the biotechnology company will post earnings per share of ($0.30) for the year. Oppenheimer has a “Outperform” rating and a $19.00 price objective on the stock.

Several other analysts have also recently commented on the company. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. ValuEngine cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Citigroup assumed coverage on Seres Therapeutics in a research report on Thursday, October 12th. They issued a “positive” rating and a $19.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. Seres Therapeutics has a consensus rating of “Buy” and a consensus price target of $18.00.

Seres Therapeutics (NASDAQ MCRB) traded down $0.37 on Monday, hitting $10.24. The stock had a trading volume of 127,735 shares, compared to its average volume of 189,600. The company has a market cap of $430.02, a price-to-earnings ratio of -4.83 and a beta of 0.22. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million during the quarter, compared to analyst estimates of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The company’s revenue was up 76.9% compared to the same quarter last year. During the same period last year, the company posted ($0.46) EPS.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC acquired a new stake in Seres Therapeutics during the second quarter valued at $114,000. Cubist Systematic Strategies LLC acquired a new stake in Seres Therapeutics during the third quarter valued at $170,000. Aperio Group LLC acquired a new stake in Seres Therapeutics during the third quarter valued at $191,000. Ironwood Investment Management LLC acquired a new stake in Seres Therapeutics during the third quarter valued at $221,000. Finally, Advisor Group Inc. boosted its position in Seres Therapeutics by 100.7% during the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 7,050 shares during the last quarter. 75.94% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/seres-therapeutics-inc-to-post-fy2022-earnings-of-0-30-per-share-oppenheimer-forecasts-mcrb/1798918.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.